What's in Octapharma's pipeline?

Octapharma has 30 drugs in our index: 5 marketed, 0 filed, 11 in Phase 3, 9 in Phase 2, 1 in Phase 1.

Which companies overlap with Octapharma's portfolio?

Top competitors by shared drug class: Baxalta now part of Shire, Kedrion S.p.A., Bio Products Laboratory, Bioverativ Therapeutics Inc., CSL Behring.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/octapharma.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Octapharma — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Octapharma pipeline: 5 marketed, 0 filed, 11 Phase 3, 9 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 11 Phase 3 9 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Gammanorm	Gammanorm	marketed			Other
Atenativ	Atenativ	marketed			Other
Balfaxar	Balfaxar	marketed			Other
Antithrombin III	Antithrombin III	marketed	Anticoagulant; plasma-derived protease inhibitor	Thrombin (Factor IIa); Factor Xa	Cardiovascular; Hematology
Panzyga	Panzyga	marketed			Other
recombinant Factor VIII	recombinant Factor VIII	phase 3
Human plasma derived antithrombin	Human plasma derived antithrombin	phase 3	Anticoagulant; serine protease inhibitor	Thrombin (Factor IIa), Factor Xa, and other activated coagulation factors	Cardiovascular; Hematology
OCTA-C1-INH	OCTA-C1-INH	phase 3	Recombinant C1-esterase inhibitor	C1-esterase inhibitor (C1-INH)	Immunology / Rare Disease
octanorm 16.5%	octanorm 16.5%	phase 3	Human albumin (colloid plasma expander)		Critical Care / Hematology
Panzyga, 10% Intravenous Solution	Panzyga, 10% Intravenous Solution	phase 3	Intravenous Immunoglobulin (IVIG)		Immunology
Newnorm	Newnorm	phase 3			Other
human VWF/FVIII concentrate	human VWF/FVIII concentrate	phase 3	Coagulation factor replacement therapy	Factor VIII	Hematology

Therapeutic area mix

Other · 12
Cardiovascular; Hematology · 2
Hematology · 2
Immunology · 2
Critical Care / Hematology · 1
Immunology / Rare Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Baxalta now part of Shire · 2 shared drug classes
Kedrion S.p.A. · 2 shared drug classes
Bio Products Laboratory · 1 shared drug class
Bioverativ Therapeutics Inc. · 1 shared drug class
CSL Behring · 1 shared drug class
CSL Limited · 1 shared drug class
Genzyme, a Sanofi Company · 1 shared drug class
Biotest · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Octapharma:

Cite this brief

Drug Landscape (2026). Octapharma — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/octapharma. Accessed 2026-06-10.